Sharemaestro Newsreel

Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com

This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 14. The filing is a standard regulatory disclosure and contains no further details within this brief report, beyond mentioning the company's stock symbol, HURA, which was up 7.39% at the time …

Capricor Therapeutics (CAPR) Stock Surges on FDA Application Amendment Plans

Outlook Therapeutics (OTLK) Q3 Earnings Miss Highlight Valuation Challenges

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100

Capricor Therapeutics (CAPR) Stock Surges on FDA Application Ame

Stifel reiterates Buy rating on Oculis stock, $40 target

Stifel has reiterated a Buy rating and a $40 price target for Oculis Holding AG (NASDAQ:OCS), based on discussions about its lead asset, privosegtor. Despite a recent stock drop and an "overvalued" assessment by InvestingPro, analysts maintain a strong buy consensus. Oculis is shifting …

Brokers Offer Predictions for RAPP Q1 Earnings

HC Wainwright Issues Pessimistic Outlook for UTHR Earnings

Noble Financial Has Pessimistic View of UNCY Q2 Earnings

HC Wainwright Has Negative Estimate for Erasca Q3 Earnings

PDS Biotechnology shareholders approve charter amendment and director elections

PDS Biotechnology Corporation shareholders have approved an amendment to the company's certificate of incorporation, increasing the number of authorized common shares from 150 million to 300 million. They also elected two Class B directors, Kamil Ali-Jackson and Ilian Iliev, and ratified KPMG US LLP …

Research Analysts Issue Forecasts for BCRX Q4 Earnings

Omeros: YARTEMLEA Is Off To A Blistering Start (NASDAQ:OMER)

Omeros Corporation has received a Buy rating due to YARTEMLEA's unexpectedly strong launch, generating $28.5 million in net sales and positive operating cash flow in its first full quarter. The drug's adoption is rapidly increasing across transplant centers, with high formulary approval rates and …

Natera (NTRA) Stock Looks Reasonable On Cash Flow But Rich On Sales

Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn

Vivos Therapeutics (NASDAQ: VVOS) will release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and will host a conference call at 5:00 p.m. Eastern Time. Management plans to discuss strategic collaborations and their anticipated effect on near-term revenue …

Why is Alpha Cognition stock surging today?

Ultragenyx (RARE): RTW Investments and Roderick Wong report 7.9% stake

RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 7.9% in Ultragenyx Pharmaceutical Inc., totaling 7,796,895 shares. This disclosure, made via a Schedule 13G filing, indicates shared voting and dispositive power over these shares, which are held by funds advised …

HC Wainwright Analysts Boost Earnings Estimates for LifeMD

HC Wainwright analysts have increased their Q4 2027 earnings per share forecast for LifeMD to $0.17 from $0.15, while maintaining a "Buy" rating and a $9 price target. Despite this, analyst sentiment remains mixed with a "Moderate Buy" consensus rating but several recent downgrades. …

Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83

Analysts have revised down their revenue estimates for LENZ Therapeutics, Inc. for 2026 to US$17.0m, a significant 21% decline, despite beating recent revenue estimates. Although loss estimates were reduced, the consensus price target for LENZ Therapeutics was cut by 16% to US$26.83, reflecting pessimism …

Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G

EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own …

Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 4.9% in Tonix Pharmaceuticals Holding Corp., which includes 814,801 shares of common stock. This stake comprises 615,025 shares issuable upon the exercise of warrants. The ownership percentage is calculated based on …

FDA approves Lantheus’ tau imaging agent for Alzheimer’s disease

The FDA has approved Lantheus Holdings Inc.'s TAUKLARIFY (florquinitau F 18 injection), a tau imaging agent for Alzheimer's disease. This radiodiagnostic agent is intended for brain PET scans in adults with cognitive impairment to identify tau neurofibrillary tangle pathology. The approval is based on …

Analyst Estimates: Here's What Brokers Think Of BridgeBio Pharma, Inc. (NASDAQ:BBIO) After Its Second-Quarter Report

This article analyzes what brokers think of BridgeBio Pharma, Inc. (NASDAQ:BBIO) following its second-quarter report. It would likely detail analyst ratings, price targets, and any changes in sentiment post-earnings, providing insights into the company's financial performance and future outlook from an investment perspective.

Q3 Earnings Estimate for AptarGroup Issued By Zacks Research

Q3 EPS Estimates for Journey Medical Cut by HC Wainwright

Sidoti Equities Analysts Raise Earnings Estimates for Kamada

Equities Analysts Set Expectations for TCRX FY2026 Earnings

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Inc. announced an inducement grant to Jennifer Larson, its new Chief Financial Officer, effective August 12, 2026. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, vesting over approximately …

Deep Track Capital (PSNL) reports 4,000,000 Personalis shares, now under 5% ownership

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G/A for Personalis, Inc. (PSNL). The filing indicates that as of June 30, 2026, the group beneficially owned 4,000,000 shares of Personalis common stock, representing 3.82% …

Stifel cuts Celcuity stock price target on refined market model

Stifel lowered its price target for Celcuity Inc. (NASDAQ:CELC) to $150 from $175, while maintaining a Buy rating, citing refined market model inputs for Revtorpyk and higher future administrative expenses. Despite the stock's strong performance, InvestingPro analysis suggests it might be overvalued, and analysts …

Celcuity Inc. Stock 12‑Month Price Target Cut to $160.64, Implies 85% Upside

Analysts have adjusted Celcuity Inc.'s average 12-month price target from $163.55 to $160.64, with individual forecasts ranging from $140 to $178 per share. This new target suggests an 85% potential upside from the Aug. 13 closing price. The consensus rating for Celcuity Inc. remains …

KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism

Quince Therapeutics reports $75.5M Q2 net loss, $116M cash as of June 30, 2026

Quince Therapeutics announced a net loss of $75.5 million for Q2 2026, with $116 million in cash, cash equivalents, and investments as of June 30, 2026. The company completed a $115 million private placement concurrent with its acquisition of Orphai and initiated a Phase …

Anteris Technologies Global (NASDAQ:AVR) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated an "overweight" rating on Anteris Technologies Global (NASDAQ: AVR) with a $15 price target, suggesting a significant upside. Despite weaker-than-expected quarterly results and insider selling, the stock maintains a "Moderate Buy" consensus rating from analysts. The company's stock has shown some …

Insider Spends US$141k Buying More Shares In Embecta

Embecta's President, Devdatt Kurdikar, recently purchased US$141k worth of company stock at US$4.70 per share, increasing his holding by 3.9%. This is the largest insider purchase in the last year, suggesting optimism for the company's future, despite the overall insider ownership being relatively low …

Embecta Corp. SVP Elguicze purchases $93,360 in common stock

Embecta Corp.'s Senior Vice President and CFO, Jacob Elguicze, recently purchased 20,000 shares of the company's common stock for $93,360. This insider purchase comes after a significant stock decline but a recent rebound, with the company trading at a low P/E ratio. The purchase …